If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysesthesia been reported in patients taking Mounjaro® (tirzepatide)?
In the SURPASS-1 and -5 studies in adults with type 2 diabetes, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.
See important safety information, including boxed warning, in the attached prescribing information.
Dysesthesia
Dysesthesia is a touch-based disorder that can result in feelings of pain, itchiness, tingling, shock, burning, and other uncomfortable sensations in the skin.1
In 2 studies comparing tirzepatide to placebo in adults with type 2 diabetes (SURPASS-1 and SURPASS-5), dysesthesia was reported by 0.4%, 0.4%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.2
Enclosed Prescribing Information
References
1Dysesthesia. Cleveland Clinic. Updated May 12, 2023. Accessed November 13, 2024. https://my.clevelandclinic.org/health/symptoms/24989-dysesthesia
2Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 04, 2024